Valuation: Access Bio, Inc.

Market Cap 70.52B 53.03M 47.04M 43.65M 39.7M 74.75M 5.04B 76.09M 524M 206M 2.63B 199M 195M 8.37B P/E 2024
-511x
P/E 2025 -1.63x
Enterprise Value -290B -218M -193M -179M -163M -307M -20.69B -313M -2.15B -844M -10.78B -817M -800M -34.39B EV / Sales 2024
-1.83x
EV / Sales 2025 -7.25x
Free-Float
99%
Yield 2024 *
-
Yield 2025 -
1 week-10.49%
Current month-5.42%
1 month-18.83%
3 months-13.02%
6 months-39.70%
Current year-47.24%
1 week 1,970
Extreme 1970
2,260
1 month 1,970
Extreme 1970
2,480
Current year 1,945
Extreme 1945
4,705
1 year 1,945
Extreme 1945
4,705
3 years 1,945
Extreme 1945
12,140
5 years 1,945
Extreme 1945
23,850
10 years 1,580
Extreme 1580
62,900
Manager TitleAgeSince
Chief Executive Officer 62 2002-01-31
Director TitleAgeSince
Chairman 62 2002-01-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-10.49%-56.60%-79.67% 52.9M
+0.20%+5.31%-17.82%+13.79% 181B
-0.73%+7.09%-0.31%+32.06% 116B
+0.49%+6.25%-20.20%+11.58% 113B
+3.83%+5.50%-44.18%-6.77% 79.83B
-0.14%+5.27%+6.74%+82.45% 65.06B
+2.79%+2.37%+15.93%+68.64% 54.35B
-1.04%+4.35%+3.50%-26.18% 52.23B
+2.41%+8.18%-12.08%+30.45% 44.15B
-1.90%+2.29%+29.72%+8.98% 32.47B
Average +0.59%+4.04%-9.53%+13.53% 73.86B
Weighted average by Cap. +0.60%+5.59%-9.70%+22.13%

Financials

2024 2025
Net sales 112B 84.57M 75.01M 69.61M 63.32M 119M 8.03B 121M 836M 328M 4.19B 317M 311M 13.35B 31.26B 23.5M 20.85M 19.35M 17.6M 33.13M 2.23B 33.72M 232M 91.08M 1.16B 88.2M 86.33M 3.71B
Net income -348M -261K -232K -215K -196K -368K -24.82M -375K -2.58M -1.01M -12.94M -981K -960K -41.27M -82.12B -61.75M -54.77M -50.83M -46.23M -87.05M -5.86B -88.61M -610M -239M -3.06B -232M -227M -9.75B
Net Debt -389B -292M -259M -241M -219M -412M -27.77B -420M -2.89B -1.13B -14.48B -1.1B -1.07B -46.17B -360B -271M -240M -223M -203M -382M -25.72B -389M -2.68B -1.05B -13.41B -1.02B -995M -42.76B
Projected Income Statement - Annual - Access Bio, Inc.
Logo Access Bio, Inc.
Access Bio, Inc. focuses on preventing and diagnosing infectious diseases early through research, development, and manufacturing of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products. The Company also launched diagnostic products, including tests for Coronavirus Disease 2019 (COVID-19), Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, dengue fever, influenza, and strep. The Company has commercialized products to combat malaria and other diseases. The Company’s product lineup includes COVID-19 Detection Kits -These kits assess the current or past presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); Rapid Diagnostic Tests (RDTs) - RDTs are used for preliminary diagnosis or emergency medical screening in facilities with limited resources; Analyzers - Designed to measure various chemicals and characteristics in biological samples; and Molecular Diagnostics - These are used to analyze biological markers in the genome and proteome.
Employees
101
Date Price Change Volume
26-10-16 ₩2,005.00 0.00% 40,203
26-10-15 ₩2,005.00 -3.84% 84,108
26-10-14 ₩2,085.00 +2.21% 27,769
26-10-13 ₩2,040.00 -5.56% 124,705
26-10-12 ₩2,160.00 -3.57% 43,352
  1. Stock Market
  2. Stocks
  3. A950130 Stock